Category Archives

One Article

Posted by John Kokish on

Why Clay Siegall is certain that the Antibody-Drug Conjugate Technology Will Replace Traditional Cancer Therapies

Dr. Clay Siegall is one of the influential figures in the biotech industry. He is renowned for creating a biotech company, Seattle Genetics, that develops treatment drugs for chronic diseases. Since its establishment in 1998, the biotech company, which is headquartered in Seattle, developed over 20 drugs and partnered with companies such as Pfizer, Genentech, and Bayer.

Education and Career Background

Dr. Siegall attributes his skills to the undergraduate zoology degree he got from the University of Maryland and the doctorate in genetics he got from George Washington University. Before he founded Seattle Genetics, he was eager to learn how technology can be used in overcoming chronic diseases. He developed an interest in cancer therapy while pursuing his undergraduate degree in zoology.

Seattle Genetics

Seattle Genetics was founded as a result of Dr. Clay Siegall’s enthusiasm to use technology in treating severe ailments. The company was approved by the Food and Drug Agency (FDA) to develop the first Antibody Drug Conjugate (ADC) products. Through the ADC technology, Seattle Genetics managed to develop over 20 drugs. Most of the drugs were developed through partnerships with other leading drug manufacturers that include Genentech and Bayer.

Under Dr. Siegall’s tenure as CEO, Seattle Genetics grew its professional team to accommodate researchers skilled in cancer therapies. Dr. Siegall also seeks to expand the company’s capacity for developing drugs in future. This initiative is geared towards fostering the firm’s existing portfolio and presence in the local and international cancer therapy market.

Dr. Siegall’s Perspectives on Modern Cancer Treatment

As one of the distinguished experts in cancer therapies, Dr. Siegall believes that medical practitioners should discard traditional cancer therapies. He is certain that Seattle Genetics is on the verge of developing more effective and tolerable drugs that would replace treatment methods such as chemotherapy.

Seattle Genetics generates most of its income from the sale of its proprietary drugs. The biotech institution’s flagship ADC-based drug is known as ADCetris. Seattle Genetics also comprises of a proactive sales staff. This professional team comprises of individuals with backgrounds in biotechnology. These individuals are in charge of pushing products to customers and monitoring the sales.